CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands		Total	Cumulative Effect, Period of Adoption, Adjusted Balance	Preferred Stock	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjusted Balance
Beginning balance (in shares) at Dec. 31, 2022				876	1,407	[1]
Beginning balance at Dec. 31, 2022		$ (477)	$ (2)	$ 0	$ 1		$ 148,545	$ (3)	$ (149,020)	$ (2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)	[1]				285
Issuance of common stock		3,025			$ 1		3,024
Stock issued in exchange transactions (in shares)	[1]				1,057
Stock issued in exchange transactions		1,716					1,716
Stock-based compensation		26					26
Net loss		(1,333)							(1,333)
Ending balance (in shares) at Mar. 31, 2023				876	2,749	[1]
Ending balance at Mar. 31, 2023		2,955		$ 0	$ 2		153,311	(3)	(150,355)
Beginning balance (in shares) at Dec. 31, 2022				876	1,407	[1]
Beginning balance at Dec. 31, 2022		(477)	$ (2)	$ 0	$ 1		148,545	(3)	(149,020)	$ (2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		4,300
Ending balance (in shares) at Dec. 31, 2023				876	4,349
Ending balance at Dec. 31, 2023		3,051		$ 0	$ 0		156,369	(3)	(153,315)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)					283
Issuance of common stock		450			$ 0		450
Conversion of advanced capital contribution to common stock (in shares)					94
Conversion of advanced capital contribution to common stock		141					141
Stock-based compensation		1					1
Net loss		(418)							(418)
Ending balance (in shares) at Mar. 31, 2024				876	4,726
Ending balance at Mar. 31, 2024		$ 3,225		$ 0	$ 0		$ 156,961	$ (3)	$ (153,733)

[1] Shares outstanding for prior periods have been restated for the 1-for-7 reverse stock split effective June 16, 2023.